GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (STU:137) » Definitions » EV-to-Revenue

Aldeyra Therapeutics (STU:137) EV-to-Revenue : (As of May. 22, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aldeyra Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aldeyra Therapeutics's enterprise value is €107.47 Mil. Aldeyra Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil. Therefore, Aldeyra Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Aldeyra Therapeutics's EV-to-Revenue or its related term are showing as below:

STU:137's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.215
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-22), Aldeyra Therapeutics's stock price is €3.643. Aldeyra Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, Aldeyra Therapeutics's PS Ratio for today is .


Aldeyra Therapeutics EV-to-Revenue Historical Data

The historical data trend for Aldeyra Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics EV-to-Revenue Chart

Aldeyra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aldeyra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aldeyra Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Aldeyra Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's EV-to-Revenue falls into.



Aldeyra Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aldeyra Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=107.471/0
=

Aldeyra Therapeutics's current Enterprise Value is €107.47 Mil.
Aldeyra Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aldeyra Therapeutics  (STU:137) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aldeyra Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3.643/0
=

Aldeyra Therapeutics's share price for today is €3.643.
Aldeyra Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aldeyra Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aldeyra Therapeutics (STU:137) Business Description

Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics (STU:137) Headlines

No Headlines